- Record: found
- Abstract: found
- Article: not found
MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.
Kathleen A Bridges
1 ,
Hiroshi Hirai ,
Carolyn A Buser ,
Colin Brooks ,
Huifeng Liu ,
Thomas A Buchholz ,
Jessica M Molkentine ,
Kathryn A Mason ,
Raymond E Meyn
Sep 01 2011
Read this article at
ScienceOpenPublisherPMC
- open (via free pdf)
- oa repository (via OAI-PMH doi match)
- oa repository (via pmcid lookup)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
Powered by 
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Radiotherapy is commonly used to treat a variety of solid tumors. However, improvements in the therapeutic ratio for several disease sites are sorely needed, leading us to assess molecularly targeted therapeutics as radiosensitizers. The aim of this study was to assess the wee1 kinase inhibitor, MK-1775, for its ability to radiosensitize human tumor cells.